Alzheimer’s Disease/Dementia News

Biogen Inc. has reported promising data from a phase 1b trial of BIIB080, an investigational antisense oligonucleotide therapy that reduced soluble tau protein in cerebrospinal fluid in patients with early Alzheimer’s disease.

Alzheon Inc. has announced positive interim findings from an ongoing phase 2 study evaluating ALZ-801, an investigational disease-modifying treatment for Alzheimer’s disease.

Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported.

A clinical biopharmaceutical company has announced completion of the clinical portion of its phase 2a multiple ascending dose study examining safety and tolerability of AL001 for dementia related to Alzheimer’s disease.

The Veterans’ Health Administration will provide coverage of a drug for the treatment of Alzheimer’s disease to veterans with early stages of the disease, according to a press release from the drug’s manufacturer.

With the increasing number of available treatments for Alzheimer’s disease, it is important for patients with cognitive concerns to openly communicate with their doctors, the Alzheimer’s Association said in a press release.

The emergence of visual artistic creativity among those with frontotemporal dementia may be linked to early lesion-induced activation of the visual cortex and may depend on environment or genetics, according to research presented in JAMA Neurology.

People who adhered more closely to the Mediterranean diet had a lower risk for dementia, regardless of genetic risk, according to data published in BMC Medicine.

A new blood test may be able to detect Alzheimer’s disease-related pathology up to 10 years before symptoms appear, according to a press release from Durin Technologies.

Biopharmaceutical company Aptinyx reported its drug for cognitive impairment was not efficacious in a phase 2 clinical trial investigating its use in patients with Parkinson’s disease and Lewy body dementia, according to a press release.